Introduction {#s1}
============

Diabetic nephropathy (DN) is the most common complication of both Type 1 and 2 diabetic patients and often results in End-stage renal disease (ESRD) ([@B46]). Approximately about 20%--40% of diabetic patients will eventually develop DN and kidney disease, and this prevalence is depending on the population and ethnicity ([@B46]). Despite advances in the diagnosis and treatment tools, DN remains a clinical burden. Early clinical diagnosis of DN is usually based on the presence of microalbuminuria (30--300 mg/day) or by the urinary albumin to creatinine ratio (\> 30 mg/g of creatinine) ([@B6]). However, in some patients with normoalbuminuria, a reduced glomerular filtration rate (GFR) was observed ([@B6]), indicating that significant glomerular damage has already occurred before the albumin detection. Recent classification of DN stage progression showed that the clinical diagnosis of urinary albumin excretion (UAE) level is already in the third stage of the DN progression ([@B46]). Therefore, identification and characterization of early biomarkers for DN become a priority. In this mini-review, we discussed the role of noncoding RNAs (ncRNAs) in DN progression and how they co-regulate each other and their target genes. Understanding of these ncRNAs regulatory networks in DN will allow for the discovery of new biomarkers and potential targets for treatment.

Noncoding RNAs (ncRNAs) {#s2}
=======================

In a single cell, the complex molecular characteristics are due to the transcriptomic profile that includes the protein-coding RNAs and the non-coding RNAs (ncRNAs) expression. Our understanding of the central dogma of the biology is that the information from the DNA is transcribed into the RNA and then are translated to proteins though, recent evidence shown that our genome consists of more ncRNAs than the protein-coding RNAs, and these ncRNAs are functional ([@B11]; [@B32]). These observations open up the new paradigm in understanding gene expression and regulation, particularly the multiple and diverse layers of molecular management of a single gene ([@B26]; [@B123]). To date, various classes of the ncRNAs have been discovered. Most of these ncRNAs are generally grouped based on their sizes, which is the small ncRNAs (\< 200 nucleotides) that include the microRNAs (miRNAs) and some of the circular RNAs (circRNAs) ([@B5]; [@B12]; [@B52]), and the large ncRNAs such as the long ncRNAs (lncRNAs) ([@B12]).

MicroRNAs (miRNAs) {#s2_1}
------------------

MiRNAs are the short single-stranded ncRNAs (size: 19--25 nucleotides), and their biogenesis and production have already extensively discussed before ([@B143]; [@B73]; [@B48]; [@B103]). The majority of the miRNAs are produced by RNA polymerases to generate the pri-miRNA transcripts from their genes in intronic clusters regions within the protein-coding genes ([@B113]). Though some miRNAs do come from their genes, and some are within the lncRNAs ([@B113]). Following that, the microprocessor complex (Drosha and DGCR8) cleaves the pri-miRNA to produce the distinctly hairpin structure of the precursor-miRNA (pre-miRNA) ([@B113]). This pre-miRNA is processed further in the cytoplasm by RNase III endonuclease Dicer to remove the stem-loop structure to produce the mature miRNA duplex ([@B113]). One of the mature miRNA duplex strands (5p or 3p strand) is incorporated into the functional miRNA-induced silencing complex (miRISC), which will bind to target messenger RNA (mRNAs) *via* complementary binding ([@B73]). A perfect complementary binding between the miRISC and the target mRNA will result in the mRNA degradation, whereas the incomplete complementary binding will lead to the translation repression ([@B113]).

Studies have shown that miRNA-mediated gene regulation is a complex and dynamic process. A single miRNA could regulate many target genes at a time, and a single target mRNA could also be regulated by several miRNAs ([@B24]; [@B103]), therefore implying the existence of the coordinated miRNA network in regulating the gene expression. Moreover, numerous evidence showing that the miRNA expression, regulatory action, and localization can change due to cellular environments ([@B35]; [@B75]). Serum starvation in multiple human cell lines has demonstrated that a significant decrease in intracellular miRNA levels with higher extracellular releases of these miRNAs either in vesicle form or as in circulating free miRNAs ([@B131]). Importantly, due to being released into extracellular fluids, these miRNAs may, therefore, can be used as biomarkers for disease.

Long Noncoding RNA (lncRNAs) {#s2_2}
----------------------------

Long noncoding RNAs (lncRNAs) refer to a group of large ncRNAs (size: \> 200 nucleotides) that do not have any protein translation capacity ([@B111]). Similar to mRNA production, lncRNAs are transcribed by the RNA polymerase II as the products of the alternative cleavage and splicing ([@B111]; [@B148]). Though unlike mRNA, lncRNAs do not necessarily require polyadenylation for their functions, and in fact, some lncRNAs exist in both polyadenylated and non-polyadenylated forms ([@B30]; [@B147]). The current classification of the lncRNAs is made based on their structure or size, localization, function, and interactions with other components ([@B31]; [@B153]). Most of these lncRNAs come from the unconserved regions of the genome, such as the intergenic, exonic, or the distal protein-coding regions ([@B31]; [@B153]). The secondary and tertiary structures of lncRNAs are quite conserved when compared to its primary structure ([@B111]; [@B31]). Due to their genomic origins, lncRNAs are, therefore, very difficult to characterize and highly diverse. In general, lncRNAs are grouped into five classes depending on their origins: 1) sense lncRNAs, 2) anti-sense lncRNAs, 3) bi-directional lncRNAs, 4) intronic lncRNAs, and 5) intergenic lncRNAs ([@B31]).

In terms of their functions, lncRNAs can modulate gene expression at the transcriptional, post-transcriptional, and translational levels. Both cis- and trans-regulation of lncRNAs have been reported, in which the cis-regulatory lncRNAs exert their function on neighboring genes whereas the trans-regulatory lncRNAs exert their function to distant genes from their transcription sites ([@B153]). Generally, there are five modes of lncRNA functions. The first one is that lncRNA acts as the microRNA sponge or also known as the naturally competing endogenous RNAs (ceRNAs), in which the lncRNA can bind to a single microRNA with a complementary sequence and silences its-mediated actions towards the target mRNAs ([@B126]). This cross-talk and co-regulation of ceRNAs have garnered new interests to unravel the multi-layered molecular regulation of a common target mRNA. The second function is that lncRNA could act as a signal due to the environmental stimulus and initiates or suppresses the transcription process by interacting with transcription factors or chromatin-modifying enzymes ([@B31]; [@B153]). The third function is that lncRNA can act the molecular decoy by interacting with the target protein and prevents its action ([@B31]; [@B153]). Fourth, the lncRNA acts as a guide for the localization of specific proteins or transcription factors and therefore activates or deactivates the genes. Lastly, the fifth function is that lncRNA acts as a scaffold platform or adaptor to allow for two or more proteins or RNA molecules to interact with each other and initiate the downstream effects ([@B31]; [@B153]).

The majority of the lncRNAs are localized in the nucleus, in which they are enriched at the chromatin region to recruit the chromatin-modifying enzymes ([@B29]; [@B153]). In some lncRNAs, a presence of a short sequence from Alu elements allows for the interactions with a nuclear matrix protein, HNRNPK, and consequently causing these lncRNAs pre-dominantly to localize in the nucleus ([@B91]). Whereas, some lncRNAs move into the cytoplasm, in which they usually regulate the mRNA translation and post-transcription modifications ([@B153]). LncRNA functions as the ceRNAs or molecular decoys are the classic example of mRNA translation regulation in the cytoplasm. Evidence of extracellular lncRNAs are limited, but several studies have managed to show that lncRNAs, similar to miRNAs, exist in the vesicle-form or circulating free in biological fluids ([@B70]). Importantly, most lncRNAs express at low levels usually, thus at a specific stage of the disease progression, their expressions arise ([@B12]; [@B52]).

Circular RNAs (circRNAs) {#s2_3}
------------------------

A back-splicing event during the transcription process that ligates a splice donor site at the upstream to an acceptor sites at downstream of the RNA transcript, produces a covalently closed loop RNA product that does not contain either 5' to 3' polarity nor a poly-adenylated tail, and this is known as the circular RNA (circRNA) ([@B15]; [@B39]; [@B122]; [@B57]). Due to its circular structure, circRNA is very stable and resistant to degradation by exoribonucleases ([@B88]; [@B15]). Similar to other ncRNAs, circRNAs do not encode for any protein products, and their biogenesis and production are well-regulated by cis-elements and trans-factors ([@B18]; [@B23]). Depending on their origins, the circRNAs are classified into four groups: 1) exonic circRNAs (ecircRNAs), 2) intronic circRNAs (ciRNAs), 3) exon-intron circRNAs (EIciRNAs), and 4) intergenic circRNAs ([@B99]; [@B159]; [@B81]). As for their sizes, circRNAs sizes range from a few hundred to thousands of nucleotides ([@B18]).

CircRNAs are highly conserved across the eukaryotes ([@B27]), and like lncRNAs, their expressions are usually low but can be tissue- and developmental stage- or disease-specific ([@B1]). Although circRNAs are known much earlier, its function and potential as biomarkers are not well understood. The most established function of circRNA is that circRNAs can act as a sponge to miRNAs to regulate gene expression ([@B15]; [@B39]; [@B57]), and in some cases, with proteins ([@B33]). In terms of the circRNAs localization, some exonic circRNAs are abundantly present in the cytoplasm ([@B61]), but no other information is available for other groups of circRNAs. However, many studies showed that circRNAs do present in extracellular vesicles and in circulating free form ([@B54]). Identification of the circRNAs' role in the regulation of gene expression has expanded the understanding and knowledge about the complex interactions between these molecular regulators, which includes the miRNAs, lncRNAs, and circRNAs.

Diabetic Nephropathy Progression {#s3}
================================

Progression to DN in diabetic patients is a very complicated process and is due to multiple factors, and previous reviews have discussed this topic extensively ([@B112]; [@B107]; [@B160]). As a summary, in diabetic settings, metabolic dysregulation leads to the alteration of kidney hemodynamics, promotes glomerulosclerosis, tubulointerstitial inflammation, and fibrosis. Both hyperglycemia and renal hypertension are the most known mediators for DN progression ([@B128]). Hyperglycemia activates the polyol pathway, hexosamine pathway and protein kinase C (PKC), which results in the accumulation of intracellular advanced glycation end products (AGEs), glomerular hyperfiltration, and hypertension ([@B120]; [@B116]; [@B87]). A key hallmark event during this stage is the activation of the renin-angiotensin system (RAS) following the changes in GFR ([@B17]; [@B3]). Elevated GFR is observed with glomerular and renal hypertrophy, and these events cause an increase in intraglomerular pressure ([@B17]). Activation of RAS cascade (from pre-renin to Angiotensin-aldosterone) leads to glomerular afferent arteriole dilatation to increase renal blood flow as a feedback mechanism to maintain GFR. Though in diabetic individuals, hyperinsulinemia, and local Angiotensin II (AngII)-aldosterone also stimulates sodium reabsorption in the proximal tubule, mesangial cell constriction, and efferent arteriolar vasoconstriction ([@B17]). Consequently, these events further increase intraglomerular pressure, tubulointerstitial inflammation, and worsen kidney damage ([@B17]). A high level of AngII-aldosterone also stimulates reactive oxygen species (ROS) production, which further damage podocyte and tubular cells ([@B17]). Increased glucose metabolism due to hyperglycemia also causes excessive production of ROS, which is highly potent and could damage the DNA and mitochondria ([@B120]; [@B87]). The activation of the growth factors such as Transforming growth factor‐β (TGFB) and inflammatory cytokines *via* PKC, mitogen-activated protein kinase (MAPK), and transcription factor nuclear factor-κB (NF-κB) result in the downstream activation of tumor necrosis factor-α (TNFA) signaling and promotes cells repair and remodeling, which further aggravates the kidney lesion and fibrosis ([@B87]). Eventually, these uncontrolled and repeated kidney damages will lead to total kidney failure.

Noncoding RNAs (ncRNAs) in DN {#s4}
=============================

Renal Hypertrophy and ECM Accumulation {#s4_1}
--------------------------------------

The presence of TGFB in the kidney usually indicates a progression towards the renal hypertrophy and extracellular matrix (ECM) accumulation, together with evidence of RAS activation during renal hypertension Recent findings in DN patients and animal models have revealed that some of these ncRNAs regulate these early events in DN development ([@B12]; [@B79]). Characterization of these ncRNAs in DN progression will allow for the discovery of early biomarkers for disease diagnosis and potential therapeutic targets, as these ncRNAs' expressions may reflect the early disease development ([@B5]; [@B12]; [@B52]).

### MicroRNAs in Renal Hypertrophy and ECM Accumulation {#s4_1_1}

MicroRNAs (miRNAs) are the most studied ncRNAs in renal-associated complications ([@B118]) ([**Table 1**](#T1){ref-type="table"}). Recent systematic review and meta-analysis in 12 of previous DN human studies ([@B141]), showed that 15 miRNAs were upregulated in DN, including miRNA-21, miRNA-181b, and miRNA-215. Whereas, seven miRNAs were downregulated in DN, including miRNA-26a, miRNA-126, miRNA-574-3p, miR-155, and miR-192 ([@B141]). Importantly, the UAE rates correlated with these six miRNAs expressions (miR-133b, miR-342, miR-30, miR-192, miR-194, and miR-215), urinary albumin-creatinine ratio associated with five miRNAs expressions (miR-192, miR-217, miR-15b, miR-34a, and miR-636), and the GFR correlated with twelve miRNAs expressions ([@B37]; [@B141]).

###### 

List of the reported noncoding RNAs in Diabetic Nephropathy.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Noncoding RNA                                                      Expression                 Sample types                                                                                Origin/population                                                                        Molecular target                                                          Function---pathogenesis
  ------------------------------------------------------------------ -------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *MicroRNAs*                                                                                                                                                                                                                                                                                                                                                  

  miR-15b                                                            Up                         Urine exosome                                                                               T2DM patients---albuminuria and non-albuminuria ([@B36])                                 NA                                                                        DN changes

  Podocyte cells                                                     Mouse cell line ([@B43])   *TNF α, IGFBP3, SEMA3A, IL1B, IL6*                                                                                                                                                                                                                             

  miR-20b                                                            Up                         Podocyte cells, HEK293T cells                                                               Mouse and human cell line ([@B134])                                                      *SIRT7*                                                                   Podocyte cells apoptosis

  miR-21                                                             Up                         renal cortical tissue                                                                       db/db DN mice (strain: C57BL/6JLepr) ([@B157])                                           *PTEN, AKT, PIK3CA*                                                       Renal cell proliferation and hypertrophy

                                                                                                Renal tissue, podocyte cells, HEK293T cells                                                 DN patients, DN STZ Sprague-Dawley rats, mouse cell line, and human cell line ([@B21])   *IL1B, TNF α, TIMP3*                                                      Podocyte cells inflammatory and apoptosis

                                                                                                Renal tissue, podocyte cells, HEK293T cells                                                 C57BL/6J \< sp \> Lepr\</sp\> ([@B140])                                                  *FOXO1, MAP1LC3A*, KHDRBS1, *P62*                                         Podocyte cells apoptosis and autophagy inhibition

  miR-22                                                             Up                         Renal tissue, NRK-52E cells                                                                 STZ Sprague-Dawley rats ([@B161])                                                        *PTEN, COL4, α-SMN1*                                                      Inhibit autophagy process and renal fibrosis

  miR-27a                                                            Up                         Kidney tubular epithelial cells, renal tissues                                              T2DM patients, rat cell line and diabetic Sprague Dawley rats ([@B55])                   *PPARG, Tgfb1, Smad3, Ccn2, Fn1, COL1*                                    Renal fibrosis

                                                                                                NRK-52E, HK-2, HBZY-1 cell lines, renal tissues,                                            db/db diabetic and cell lines ([@B119])                                                  *Gabpa, Itln1*                                                            The pro-inflammatory response, oxidative stress

                                                                                                podocyte cells                                                                              T2DM patients with DN, murine cell line and diabetic rats ([@B165])                      *Pparg, Ctnnbip1, Snai1, Acta2*                                           Podocyte cells injury and apoptosis

  miR-34a                                                            Up                         Urine exosomes                                                                              T2DM patients---albuminuria and non-albuminuria ([@B36])                                 NA                                                                        DN changes

  miR-130a                                                           Up                         Urine exosomes, renal tissues, human mesangial cells                                        T1DM patients with DN, DN mice, and human cell line ([@B10])                             NA                                                                        DN changes

  miR-130b                                                           Up                         Renal tissues, mesangial cells                                                              DN patients and cell line ([@B94])                                                       *TGFB1, COL1, COLIV, FN, t‐Smad2/3, p‐Smad2/3, and SMAD4*                 Renal fibrosis, and extracellular matrix accumulation

  miR-133b                                                           Up                         Urine exosomes                                                                              T2DM patients---albuminuria and non-albuminuria ([@B37])                                 *TGFB1*                                                                   DN changes

                                                                                                Renal cortex, human proximal tubule cell line, HEK293T cells                                OLETF mice and human cell line ([@B125])                                                 *CDH1, TGFB1, COL1, FN, ACTA2, SIRT1*                                     Epithelial-mesenchymal transition, and renal fibrosis

  miR-134-5p                                                         Up                         Renal tissues, podocyte cells                                                               Db/db mice ([@B110])                                                                     *BCL2*                                                                    Podocytes apoptosis

  miR-135a                                                           Up                         Serum, renal tissues, mesangial cells, HEK293T cells                                        DN patients, healthy control, and db/db mice, cell line ([@B51])                         *TRPC1, FN, COL1, TGFB1, PCNA, CCND1, P21, CDH, VIM*                      Mesangial cells proliferation, increase extracellular matrix proteins, and renal fibrosis

  miR-141                                                            Up                         Mesangial cells                                                                             Human cell line ([@B85])                                                                 *IRS2*                                                                    Renal hypertrophy, inflammation, and cell apoptosis

  miR-145                                                            Up                         Urine exosomes, renal tissues, human mesangial cells                                        T1DM patients with DN, DN mice, and human cell line, ([@B10])                            *STAT1, TGFB1*                                                            Mesangial cells damage

  miR-155-5p                                                         Up                         Proximal tubular cells                                                                      Human Cell line ([@B139])                                                                *SIRT1, LC3 II, ATG5*                                                     Autophagy

  miR-181a                                                           Up                         Plasma                                                                                      DN patients ([@B13])                                                                     NA                                                                        Microvascular damage

  miR-181b                                                           Up                         Glomerular mesangial cells, renal biopsy                                                    DN patients ([@B168])                                                                    *TIMP3*                                                                   Mesangial cells apoptosis

  miR-182-5p                                                         Up                         Renal biopsy, podocyte cells                                                                DN patients and cell line ([@B101])                                                      *CD2AP, FOXO1, BCL2*                                                      Podocyte cells injury and apoptosis

  miR-192                                                            Up                         Renal cortical tissues, mesangial cells                                                     db/db mice ([@B67])                                                                      *Tgfb1, Akt, Pten, E box*                                                 Glomerular hypertrophy, mesangial cells expansion, Renal fibrosis, extracellular matrix accumulation, and tubular damage Glomerular hypertrophy and mesangial cells expansion

                                                                                                Urine extracellular vesicles, renal tubular epithelial cells, mesangial cells,              Albuminuria patients and human cell line ([@B64])                                        *TGFB1*                                                                   Tubular and mesangial cells damage

                                                                                                Renal biopsy                                                                                DN patients ([@B74])                                                                     *TGFB1, ZEB1, CDH1*                                                       Tubulointerstitial fibrosis

  miR-194                                                            Up                         Urine extracellular vesicles, human renal tubular epithelial cells, human mesangial cells   DN patients with T2DM and human cell line ([@B64])                                       *AKT, TRAF6*                                                              Tubular and mesangial cells damage

  miR-195                                                            Up                         Plasma and urine                                                                            CKD patients ([@B114])                                                                   NA                                                                        DN changes

  miR-199b                                                           Up                         Renal cortex, human proximal tubular epithelial cells                                       OLETF mice and human cell line ([@B124])                                                 *CDH1, TGFB1, COL1, FN, ACTA2, SIRT1*                                     Epithelial-mesenchymal transition, and renal fibrosis

  miR-200                                                            Up                         Renal cortex tissues, mesangial cells                                                       db/db mice ([@B105])                                                                     Fog2*, Pi3k, Tgfb1*                                                       Glomerular mesangial hypertrophy

  miR-212                                                            Up                         Renal, plasma                                                                               Sprague-Dawley rats ([@B38])                                                             *Angiotensin, MAPK3*                                                      Hypertension in renal

  miR-215                                                            Up                         Urine extracellular vesicles, renal tubular epithelial cells, mesangial cells               Albuminuria patients and human cell line ([@B64])                                        *TGFB1*                                                                   Tubular and mesangial cells damage

  miR-216a                                                           Up                         Renal cortex tissues, mesangial cells                                                       db/db mice ([@B67])                                                                      *Tgfb, Akt, Pten, Zeb1*                                                   Glomerular hypertrophy and mesangial cells expansion

  miR-217                                                            Up                         Renal cortex tissues, mesangial cells                                                       db/db mice ([@B67])                                                                      *Tgfb, Akt, Pten, Zeb1*                                                   Glomerular hypertrophy and mesangial cells expansion

  miR-320                                                            Up                         Renal cortex tissues, podocyte cells                                                        Db/db mice ([@B53])                                                                      *Mafb*                                                                    Podocyte cells injury and apoptosis

  miR-324-3p                                                         Up                         Glomerular cells, tubular cells                                                             Munich Wistar Fromter mice ([@B95])                                                      Angiotensin, Ac-SDKP*, Prep*                                              Renal fibrosis

  miR-337                                                            Up                         Renal tissues, mesangial cells                                                              DN mice and human cell line ([@B130])                                                    *TGFB*                                                                    Mesangial cells expansion, and renal toxicity and fibrosis

  miR-342                                                            Up                         Urine exosomes                                                                              T2DM patients---albuminuria and non-albuminuria ([@B37])                                 *TGFB1*                                                                   DN changes

  miR-370                                                            Up                         Renal tissues, mesangial cells                                                              DN mice ([@B155])                                                                        *Cnpy1*                                                                   Mesangial cells proliferation and extracellular matrix accumulation

  miR-377                                                            Up                         Renal tissues, mesangial cells                                                              DN mice and human cell line ([@B130])                                                    *FN, PAK1, SOD1, SOD2, TGFB*                                              Renal toxicity and fibrosis

                                                                                                Renal cortex, mesangial cells                                                               T2DM db/db mice and mice cell line ([@B69])                                              *Tgfb1, Akt, Erk, Chop, Edem3*                                            Endoplasmic reticulum stress, and glomerular extracellular matrix and hypertrophy

  miR-379                                                            Up                         Renal tissues, mesangial cells                                                              db/db mice and mouse cell line ([@B69])                                                  *Tgfb1, Akt, Erk, Chop, Edem3*                                            Renal toxicity and fibrosis, endoplasmic reticulum stress, extracellular matrix accumulation, and podocyte cells injury

  miR-382                                                            Up                         Renal tissue, mesangial cells                                                               STZ mice ([@B137])                                                                       *Foxo1*                                                                   Renal hypertrophy and extracellular matrix accumulation

  miR-4449                                                           Up                         Serum exosomes                                                                              DN patients ([@B71])                                                                     NA                                                                        Angiogenesis

  miR-451                                                            Up                         Plasma and urine                                                                            CKD patients ([@B114])                                                                   NA                                                                        DN changes

                                                                                                Renal tissues, primary mouse mesangial cells                                                DN mice, and cell line ([@B158]),                                                        Ywhab, P38 Mapk                                                           Renal fibrosis and glomerular cells proliferation

  miR-494                                                            Up                         Renal tissues, mesangial cells                                                              db/db mice and cell line ([@B69])                                                        *Tgfb1, Akt, Erk, Chop*                                                   Renal toxicity and fibrosis

  miR-495                                                            Up                         Renal tissues, mesangial cells                                                              db/db mice and cell line ([@B69])                                                        *Tgfb1, Akt, Erk, Chop*                                                   Renal toxicity and fibrosis

                                                                                                Urine                                                                                       T1DM patients with DN ([@B25])                                                           NA                                                                        DN changes

  miR-503                                                            Up                         Renal tissues, podocyte cells                                                               STZ mice ([@B156])                                                                       *E2f3*                                                                    Podocyte cells injury and apoptosis

  miR-636                                                            Up                         Urine exosome                                                                               T2DM patients---albuminuria and non-albuminuria ([@B36])                                 NA                                                                        DN changes

  miR-770-5p                                                         Up                         Podocyte cells                                                                              Mice cell line ([@B162])                                                                 *Triap1*                                                                  Podocyte cells apoptosis and cells death

  miR-181a                                                           Down                       Renal tissue                                                                                Hypertensive and normotensive patients ([@B97])                                          *AIFM1, APOE, RENIN*                                                      Hypertension in renal

  miR-25                                                             Down                       Serum, renal tissue, and HK-2 cells                                                         DN patients and human cell line ([@B82])                                                 *PTEN, AKT*                                                               Renal tubular epithelial cell injury and apoptosis, mesangial cells injury, and glomerular hypertrophy

                                                                                                Renal tissue                                                                                STZ Sprague-Dawley rats ([@B42])                                                         *NOX4*                                                                    

                                                                                                Glomeruli, mesangial cell                                                                   STZ mice and cell line ([@B104])                                                         *p-MeCP2, Hipk2, Tgfb*                                                    Oxidative stress

  miR-26a                                                            Down                       Renal biopsy, STZ mice, and human podocyte cells                                            DN patients, STZ mice, and human cell ([@B72])                                           *TGFB, CTGF, SMAD, CTDSP2, CTDSPL*                                        Extracellular matrix accumulation

  miR-29a                                                            Down                       Glomeruli, podocyte cells                                                                   STZ mice ([@B86])                                                                        Nephrin                                                                   Podocyte cell apoptosis

                                                                                                Mesangial cells                                                                             Mice and cell line ([@B127])                                                             *Cb1r, Pparg*                                                             Renal hypertrophy

  miR-30                                                             Down                       Urine exosomes                                                                              T2DM patients---albuminuria and non-albuminuria ([@B37])                                 NA                                                                        DN changes

  miR-93                                                             Down                       Renal microvascular endothelial cells, podocyte cells                                       Mice cell line and diabetes db/db mice ([@B89])                                          *Vegfa, Mcm7*                                                             Podocyte cells damage

                                                                                                Podocyte cells, renal tissues                                                               Mice cell line and Cg-Dock7^m+/+^Lepr^db/J^ mice ([@B8])                                 *Msk2*                                                                    

                                                                                                Renal tissue, human renal tubular cells                                                     DN patients and human cell line ([@B93])                                                 *ORAI1, TGFB1*                                                            Renal fibrosis and endothelial mesenchymal transition

  miR-155                                                            Down                       Urine exosomes, blood, renal tissues                                                        DN patients and C57BL6/J mice ([@B10])                                                   NA                                                                        Podocyte cells injury

  miR-205                                                            Down                       Renal tubules epithelial cells                                                              Human cell line ([@B102])                                                                *EGLN2, VEGF GLUT1, HIF-1α*                                               Renal injury

  miR-214                                                            Down                       Renal, human renal proximal tubular epithelial cells                                        DN mice and human cell line ([@B151])                                                    *UCP2*                                                                    Oxidative stress

  miR-374a                                                           Down                       Renal biopsy, human proximal tubular epithelial cells                                       DN patients and human cell line ([@B150])                                                *CCL2*                                                                    Induce inflammatory response

  miR-423-5p                                                         Down                       Renal biopsy, podocyte cell                                                                 DN patients and mice cell line ([@B146])                                                 *NOX4*                                                                    Oxidative stress and podocyte cells death

  miR-424                                                            Up                         Urine exosomes, renal tissues, human mesangial cells                                        T1DM patients with DN, DN mice, and human cell line, ([@B10])                            NA                                                                        DN changes

  miR-455-3p                                                         Down                       Mesangial cells, proximal tubular epithelial cells                                          Human cell line ([@B145])                                                                *ROCK2*                                                                   Inflammation and fibrosis

  miR-574-3p                                                         Down                       Plasma                                                                                      DN patients ([@B13])                                                                     *ANGPT2/ANGPT1, IGF1*                                                     Effects renal function (eGFR and creatinine)

  miR-663                                                            Down                       Renal tissue                                                                                Hypertensive and normotensive patients ([@B97])                                          *AIFM1, APOE, RENIN*                                                      Hypertension in renal

  miR-874                                                            Down                       Renal cortex                                                                                STZ mice ([@B152])                                                                       *TLR4, IL6, IL1B,*\                                                       Podocyte cells proliferation and apoptosis
                                                                                                                                                                                                                                                                                     *TNFA*                                                                    

  Let-7a-5p                                                          Down                       Renal tissue, mesangial cells                                                               db/db mice and cell line ([@B142])                                                       *HMGA2*                                                                   Renal hypertrophy and apoptosis

  *Long noncoding RNAs*                                                                                                                                                                                                                                                                                                                                        

  ERBB4-IR                                                           Up                         Renal tissue                                                                                C57BL/6J mice ([@B163])                                                                  *Smad3, Tgfb*                                                             Renal fibrosis

                                                                                                Renal cortex, mesangial cells, tubular epithelial cells                                     db/db mice and mice cell ([@B125]) ([@B125])                                             *Smad3, Tgfb1, miR-29b*                                                   

  GAS5                                                               Up                         Human renal tubular epithelial cell                                                         Human cell line ([@B92])                                                                 *miR-27a, P53, CASP3, BNIP3*                                              Renal tubular epithelial cells apoptosis

  Gm4419                                                             Up                         High glucose mesangial cells                                                                Mice cells ([@B154])                                                                     *Nfkb*                                                                    Renal inflammation and fibrosis.

  GM5524                                                             Up                         Renal tissues, podocyte cells                                                               db/db mice ([@B41])                                                                      *CASP3, BAX,* LC3I, LC3II *Atg5, Atg7, Bcl2*                              Podocyte cells apoptosis and cells autophagy

  GM6135                                                             Up                         Mesangial cells                                                                             db/db mice ([@B63])                                                                      *TLR4, miR‐203*                                                           Mesangial cells proliferation and apoptosis

  LncRNA CJ241444-miR-192                                            Up                         Renal cortical tissues, mesangial cells                                                     Obese type 2 diabetic db/db mice and mouse cells ([@B68])                                *Tgfb, Akt, Col1a2, Col4A1, Smad, Ets1, miR-192*                          Mesangial cells fibrosis

  Lnc-MGC                                                            Up                         Renal tissue, mesangial cells                                                               STZ mice and human cell ([@B69])                                                         *TGFB1, SMAD, CHOP*                                                       Renal toxicity and fibrosis, glomerular hypertrophy, extracellular matrix accumulation, and podocyte cells injury

  LncRNA NR_033515                                                   Up                         Serum, HEK293 T cells,mesangial cells                                                       DN patients and mouse cell ([@B44])                                                      *HAVCR1, PCNA, CCND1TGFB1, P38, ASK1, FN, ACTA2, CDH, VIM, miR-743b-5p*   EMT and cell proliferation

  Metastasis associated lung adenocarcinoma transcript 1 (MALAT-1)   Up                         Umbilical vein endothelial cells, STZ mice                                                  Human cell line and mice ([@B108])                                                       *SAA3, TNF-α, IL-6*                                                       Renal inflammation and fibrosis\
                                                                                                                                                                                                                                                                                                                                                               Microvascular inflammation

                                                                                                Podocyte cells, HEK‐293 cells                                                               Human, C57BL/6 mice, cell line ([@B56])                                                  *CTNNBIP1, SRSF1*                                                         Podocyte cells damage

                                                                                                Renal tissues, proximal tubular epithelial cells                                            Sprague Dawley rats and human cell line ([@B83])                                         *miR-23c, ELAVL1, NLRP3*                                                  Renal tubular epithelial cell pyroptosis

                                                                                                Serum                                                                                       ESRD patients with diabetes ([@B40])                                                     *miR-499a*                                                                DN changes

  NEAT1                                                              Up                         Renal tissues                                                                               Diabetic mice ([@B59])                                                                   *Akt, Mtor, Tgfb1, Fn, ColIv*                                             Mesangial cell proliferation and fibrosis

                                                                                                Renal tissues                                                                               Sprague--Dawley rats ([@B138])                                                           *Zeb1, miR‐27b‐3p, Ask1, fibronectin, Tgfb1*                              

  Plasmacytoma variant translocation (PVT1)                          Up                         Blood                                                                                       Gila River Indian Community with T2DM and DN T1DM patients with DN ([@B50])              NA                                                                        DN changes

                                                                                                Blood, human primary renal cell                                                             Pima Indians with T1DM and T2DM, and human cell line                                     NA                                                                        

                                                                                                Mesangial cells                                                                             Human cell line ([@B4])                                                                  *FN1, COL4A1, SERPINE1, TGFB1*                                            Extracellular matrix accumulation and mesangial cells fibrosis

  CASC2                                                              Down                       Serum, renal tissue                                                                         DN patients ([@B135])                                                                    NA                                                                        Podocyte cells deaths

                                                                                                Serum, podocyte cells                                                                       DN patients and mouse ([@B149])                                                          *JNK1*                                                                    

  CYP4B1-PS1-001                                                     Down                       Mesangial cells, renal cortex                                                               db/db mice ([@B136])                                                                     *Ncl*                                                                     Renal proliferation and fibrosis

                                                                                                renal tissue, mesangial cells, HEK293T                                                      C57BL/KsJ db/db mice, and human and mouse cell line ([@B132])                            *PCNA, CCND1, FN, COLI*                                                   Mesangial cells proliferation and fibrosis

  ENSMUST00000147869                                                 Down                       Renal cortex                                                                                db/db and db/m mice ([@B133])                                                            *Cyp4a12a*                                                                Mesangial cells proliferation and fibrosis

  GM15645                                                            Down                       Renal tissue, podocyte cells                                                                db/db mice ([@B41])                                                                      *CASP3, BAX,* LC3I, LC3II *Atg5, Atg7, Bcl2*                              Podocyte cells apoptosis and cells autophagy

  LINC01619                                                          Down                       Renal biopsy, cortex, podocyte cell                                                         T2DM patients, and STZ Sprague Dawley rats ([@B9])                                       *FOXO1, ROS, CHOP, GRP78, miR-27a*                                        Podocyte cells injury and apoptosis and endoplasmic reticulum stress

  LncRNA 1700020I14Rik                                               Down                       Renal tissue, mesangial cells                                                               db/db and db/m mice ([@B84])                                                             *Sirt1, Hif1a, Col4, Fn, Tgfb1, miR-34a-5p*                               Mesangial cells proliferation and fibrosis

  lncRNA RIAN                                                        Down                       NIH3T3 cells and renal tissue                                                               Mice and cell line ([@B14])                                                              *Acta2, Col1a1, Smad2, Smad3, miR-150*                                    Myofibroblast formation

  Taurine up-regulated 1 (TUG-1)                                     Down                       Renal cortex, mesangial, podocytes cells                                                    db/db and db/m mice and cell line ([@B90])                                               *Ppargc1a*                                                                Podocyte cells death and extracellular matrix accumulation Reduce glomerular filtration rates and podocyte cells apoptosis

                                                                                                Renal cortex, mesangial cells                                                               C57BL/KsJ-db/db mice and mice cell line ([@B34])                                         *miR-377, Pparg,* Serpine1*, Tgfb1, Fn, Col Iv*                           Extracellular matrix accumulation of mesangial cells

                                                                                                Renal tissues, podocyte cells                                                               Sprague Dawley rats and mice cell line ([@B78])                                          *Traf5*                                                                   Podocyte cells apoptosis

                                                                                                Renal biopsy, podocyte cells                                                                DN patients and human cell line ([@B117])                                                PGC‐1α, CHOP                                                              Podocyte cells apoptosis and endoplasmic reticulum stress

  Myocardial infarction associated transcript (MIAT)                 Down                       Proximal convoluted tubule, proximal tubular epithelial cell line (HK-2)                    STZ Wistar rats and cell line ([@B164])                                                  *Nrf2, Acta2, Smad2/3, Col1a1*                                            Renal cell apoptosis and fibrosis

  *Circular noncoding RNAs*                                                                                                                                                                                                                                                                                                                                    

  circRNA_15698                                                      Up                         Renal cortex, mesangial cells                                                               C57BL/KsJ‐db/db mice ([@B57])                                                            *Tgfb1, Col1a1*, *Col4a1* and *Fn, miR‐185*                               Renal fibrosis
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Among these reported miRNAs, some are shown to regulate RAS and renal hypertension ([@B49]) ([**Table 1**](#T1){ref-type="table"}). For example, investigation in the human kidney cell line showed that miR-663 directly regulates the expression of renin (*REN*) and apolipoprotein E (*APOE*) genes, and miR-181a directly regulates the expression of *REN* and apoptosis-inducing factor, mitochondrion-associated-1 (*AIFM1*) genes ([@B97]). Inhibition of these miRNAs expression will increase their target genes expressions like the renin and, thus, induce the RAS cascade-production of angiotensin I/II and aldosterone, which is a significant dysregulation event in the early DN progression ([@B97]). Therefore, the reduction of both miRNAs' expression (miR-181a and miR-663) in the patients can be used as the early biomarkers of DN, since their reduced expression may reflect the start of the RAS activation. Moreover, both miR-181a and miR-663 expressions were reduced in hypertensive renal tissue ([@B97]), and serum expression of miR-181a can be a biomarker for the renal miR-181a ([@B98]) thus, confirming that these miRNAs can serve as biomarkers for early dysregulation of RAS in DN patients. Besides that, Ang II itself can increase five downstream miRNAs expressions, including miR-29b, miR-129-3p, miR-132, miR-132-5p, and miR-212, as reported in a human kidney cell line study with the overexpression of Angiotensin II receptor type 1 (*AT1R*) ([@B62]). Though, only some of these miRNAs are involved in DN, particularly the miR-29b and its role in kidney fibrosis and cell death ([@B124]). Understanding the roles of miRNAs in RAS activation is important, as RAS blocker therapy or treatment is currently one of the main treatments for DN patients ([@B62]).

Another early dysregulated miRNAs in DN progression is the miR-192 ([@B67]; [@B74]; [@B64]; [@B7]). MiR-192 is the most abundant miRNA in the kidney, in which its high expression protects the kidney function ([@B74]). In DN patients and mice model, miR-192 expression was reduced as the DN progresses ([@B67]; [@B74]; [@B64]). This reduction of miR-192 expression removed the suppression of the E box repressors, *Zeb1*, and *Zeb2* expressions, which are the inducers of the TGFB pathway, and further promoted TGFB-induced downstream activation of other miRNAs to promote renal hypertrophy and ECM accumulation ([@B66]). One example of the TGFB-downstream miRNAs is the miR-21, which is the most well-known miRNA in DN and its expression was upregulated in both human DN and mice models ([@B157]; [@B114]; [@B21]; [@B140]). MiR-21 negatively regulates the expression of Phosphatase and tensin homolog (*PTEN*) and matrix metalloproteinases ([@B16]). Hyperglycemia condition upregulates miR-21 expression in the plasma and urine samples ([@B114]). In a study of DN patients, miR-21 expression was elevated in the kidney biopsy and correlated with the podocyte cell damage, together with a reduced metalloproteinase inhibitor-3 (*TIMP3*) expression ([@B21]). *TIMP3* is an important regulator of a healthy kidney, and the reduction of its expression increases the podocyte cell death ([@B21]). Another target of miR-21 is the forkhead box O1 (*Foxo1*), which was down-regulated in DN-induced by hyperglycemia condition ([@B140]). Treatment of a currently clinical-trialed DN drug, Atrasentan (an endothelin-1 receptor antagonist) reduced miR-21 expression, restored the *Foxo1* expression, and thus promoted renal autophagy ([@B140]). Therefore, following TGFB response, majority of these downstream network of miRNA activates the PI3K/AKT/mTOR pathway, by targeting the *PTEN* (miR-216a, miR-217, miR-21, miR-22, miR-25, and miR-214) ([@B67]; [@B28]; [@B82]; [@B161]), collagen type I alpha1 (*COLIA1*), Collagen IV (*COL4*), and Fibronectin (*FN*) (miR-130b) ([@B94]), PI3K inhibitor (*Fog2*) (miR-200 family) ([@B105]), Tyrosine 3-monooxygenase (*Ywhab*) (miR-451) ([@B158]), DEP domain-containing mTOR-interacting protein (*Deptor*) (miR-181a) ([@B96]), Protein canopy homolog-1 (*Cnpy1*) (miR-370) ([@B155]), high−mobility group AT−hook-2, *Hmga2* (let-7a-5p) ([@B142]), Insulin receptor substrate-2, *IRS2* (miR-141) ([@B85]), forkhead box proteins, and *Foxo1* (miR-382) ([@B137]) genes. Some of these miRNAs are found in circulating bio-fluids and therefore, could potentially be as biomarkers.

In contrast to the pro-DN miRNAs, miR-93 is the protective miRNA, with its expression was reduced in an animal model of DN, and miR-93 is a direct regulator of the vascular endothelial growth factor A (*Vegfa*) ([@B89]) and *Msk2*, a ribosomal S6 kinase of serine/threonine ([@B8]) expressions. Overexpression of miR-93 prevented the chromatin remodeling in podocyte cells after induction of hyperglycemia condition, *via* the suppression of *Msk2* expression (a kinase that phosphorylates histone, H3S10) ([@B8]). Thus, making miR-93 as the potential therapeutic option to alleviate DN. Importantly, miR-93 also negatively regulates the Calcium release-activated calcium channel protein-1 (*ORAI1*), and reduction of miR-93 expression in DN caused an increase in *ORAI1* expression and subsequently promoted TGFB-mediated ECM accumulation and fibrosis ([@B93]). Excessive ECM accumulation will eventually lead to glomerulosclerosis; therefore, it is the first and crucial step for progressive renal function loss.

### Long Noncoding RNAs in Renal Hypertrophy and ECM Accumulation {#s4_1_2}

Several lncRNAs are involved in the regulation of renal hypertrophy and ECM accumulation, though the evidence is quite limited ([**Table 1**](#T1){ref-type="table"}). One such lncRNA is the Plasmacytoma Variant Translocation-1 (PVT1), which is the first lncRNA to be associated with DN patients ([@B100]; [@B4]). Hyperglycemia induced higher PVT-1 expression and caused mesangial cell expansion through ECM accumulation of the FN, TGFB1, type IV collagen (COL4A1), and type 1 plasminogen activator inhibitor (PAI1) ([@B4]), as well as the myosin (MYC) proteins ([@B50]). The knockdown of PVT-1 expression significantly caused the reduction of these molecules ([@B4]). Another reported lncRNA is the Nuclear Enriched Abundant Transcript-1 (NEAT1), which is also highly expressed due to hyperglycemia, and NEAT1 interacts with AKT/mTOR pathway ([@B59]). Inhibition of NEAT1 expression in an animal model of DN causes a reduction of TGFB1, FN, and COL4A1 production ([@B59]). Similarly, lncRNA ERBB4-IR also promotes renal fibrosis *via* the activation of the TGFB/SMAD3 pathway ([@B163]; [@B125]). Interestingly, knockdown of this lncRNA ERBB4-IR in DN mice protected the mice from having high albuminuria and creatinine, as well as prevented renal fibrosis ([@B125]).

Opposite to PVT-1 and NEAT-1, a hyperglycemic condition caused downregulation of lncRNA, CYP4B1-PS1-001 expression, which increases nucleolin (NCL) protein expression ([@B132]; [@B136]). An increase in this protective lncRNA expression reduces the production of FN, COL4A1, and proliferation markers (PCNA and CCND1) in DN mice ([@B136]). Another protective lncRNA is the lncRNA ENSMUST00000147869 that negatively regulate ECM protein accumulation in a hyperglycemic condition in DN mice ([@B133]). Though, the exact role of this lncRNA is unknown.

### LncRNA-miRNA Interactions in Renal Hypertrophy and ECM Accumulation {#s4_1_3}

Understanding the interactions between miRNAs and lncRNAs to regulate genes involved in DN are important, as they will unravel the critical steps in DN progression. For example, in ECM accumulation ([**Figure 1**](#f1){ref-type="fig"}), previous studies in DN mice showed that interactions of lncRNA CJ241444-miR-192 activates TGFB1/SMAD signaling ([@B68]) and lncRNA Erbb4-IR-miR-29b promotes the collagen genes expression, ECM accumulation and kidney injury ([@B125]). In both of the studies ([@B68]; [@B124]), the lncRNAs act as the miRNA sponge to exert the outcomes. Similarly, another reported lncRNA-miRNA interaction in DN is the lncRNA PVT-1 that mediates the ECM proteins accumulation *via* the actions of its-derived miRNAs, miR-1207-5p, and miR-1207-3p ([@B4]). Under the hyperglycemic condition, higher expression of both PVT-1 and its miRNAs led to an increase of the TGFB1/SMAD signaling pathway and further promoted the ECM protein accumulation and oxidative stress ([@B4]). Another example is the miR-379 cluster that consists of 40 miRNAs that are regulated by ER stress in DN, and lncRNA lncMGC is also hosted in this same cluster ([@B69]). LncMGC controls the expression of the miR-379 cluster, and the upregulation of this miRNAs cluster induces ECM accumulation and hypertrophy ([@B69]). Thus, inhibition of lncMGC expression could be used as a potential therapy for DN to reduce the miR-379 cluster's effects, following the ER stress. Besides that, lncRNA NEAT1 inhibition is also a potential therapeutic therapy, as this NEAT1 inhibition leads to the suppression of ECM accumulation, *via* the reduction of ASK1, FN, and TGFB1 production ([@B138]). This NEAT1-mediated ECM suppression was due to its interaction with miR-27b-3p, and its target, the TGFB inducer, *Zeb1*, in which NEAT1 is no longer suppressing the miR-27b-3p, which in turns activates the suppression of *Zeb1*, and thus can prevent DN progression ([@B138]). Administration of the anti-apoptotic lncRNA, TUG-1, suppresses the miR-377 expression to increase the expression of miR-377's target gene *PPARG* and thus prevents ECM accumulation in DN mice ([@B34]). Therefore, treatment to increase TUG-1 expression may be beneficial to prevent DN development, though further studies are needed to confirm this potential treatment. By understanding these interactions between lncRNAs and their target miRNAs, these findings will allow for therapeutic targets selection to prevent ECM accumulation and possibly DN progression.

![Schematic diagram showing the roles of noncoding RNAs in contributing to diabetic nephropathy. ECM, extracellular matrix; ER, Endoplasmic reticulum; black arrow, positive regulation; red arrow, negative regulation.](fphar-11-00191-g001){#f1}

Oxidative Stress and Inflammation {#s4_2}
---------------------------------

### MiRNAs in Oxidative Stress and Inflammation {#s4_2_1}

As for inducing the oxidative stress, miR-205 directly regulates the expression of Egl-9 Family Hypoxia Inducible Factor 2 (*EGLN2*), and miR-205 expression was reduced due to oxidative stress ([@B102]). Upon reduction of miR-205 expression, *EGLN2* expression was increased and caused the reduction of the HIF-2A protein, and consequently increased the reactive oxygen species (ROS) level ([@B102]). Another oxidative stress-related miRNA is the miR-377, and its expression was higher in the renal tissue of DN mice ([@B130]), thus caused a reduction in the expression of superoxide dismutase 2 (*SOD2*), an enzyme responsible for removing free superoxide radicals. Several other miRNAs also regulate endoplasmic reticulum (ER) and oxidative stress in renal cells, such as miR-379 cluster, miR-494 ([@B69]), miR-15b ([@B36]; [@B43]; [@B141]), and miR-135a ([@B51]). Interestingly, miR-214 expression was reduced in peripheral blood of DN mice and overexpression of miR-214 in human renal proximal tubular epithelial cells prevented oxidative stress *via* upregulation of mitochondrial uncoupling protein-2 (*UCP2*) expression and its downstream pathway, the ROS/AKT/mTOR signaling pathway with significant reduction of ROS ([@B151]). Since the miR-214 reduction in circulating blood samples of DN mice was consistent with the renal expression of miR-214, and its regulation of the oxidative stress in kidney cells, thus miR-214 can be used as a potential oxidative stress biomarker. Another miRNA is the miR-25 that negatively regulates NADPH oxidase-4 (*Nox4*) expression (an enzyme that produces ROS), and its expression was reduced in the renal tissue of DN rats ([@B42]). Importantly, the miR-25 expression is also regulated by Homeodomain-interacting protein kinase-2 (Hipk2) ([@B104]), indicating a complex regulation of HIPK2-miR-25-*NOX4* in the maintenance of ROS. Furthermore, *NOX4* gene expression is also regulated by miR-423-5p, that were downregulated in kidney tissues of DN patients ([@B146]), further re-affirm the complex and tight regulation of *NOX4* gene.

In terms of inflammation, miR-27a is a pro-inflammatory miRNA that negatively regulates the expression of nuclear factor erythroid 2-like 2 (*NRF2*) and peroxisome proliferator-activated receptor γ (*PPARG*), thus promotes the secretion of pro-inflammatory cytokines in DN animal and cell line models ([@B55]; [@B119]; [@B166]). Intriguingly, miR-27a expression is also negatively regulated by *Itln1*, an adipokine that usually reduced in metabolically dysregulated individuals ([@B119]), indicating its role in metabolic syndrome. Another inflammatory miRNA is the miR-324-3p, and its expression was higher in glomerular and tubular tissues of DN mice ([@B95]). Increased of this miR-324-3p expression led to renal inflammation *via* the suppression of prolyl endopeptidase gene expression (*Prep*), an enzyme that is responsible for regulating angiotensin metabolism ([@B95]). In contrast to that, miR-374a is the anti-inflammatory miRNA in DN, which negatively regulates the expression of Monocyte chemo-attractant protein-1 (*CCL2*), a pro-inflammatory chemokine ([@B150]). In DN patients, restoration of miR-374a expression in renal tubular epithelial cells prevented the inflammatory response ([@B150]). Similarly, miR-874 negatively regulates the expression of Toll-like receptor-4 (*Tlr4*), and thus prevents the secretion of pro-inflammatory cytokines in DN mice ([@B152]). Another anti-inflammatory miRNA is the miR-455-3p that negatively regulates the expression of coil-containing protein kinase 2 (*ROCK2*), and consequently reduced the inflammatory cytokines and fibrosis markers in a human kidney cell line ([@B145]). Identification of these anti-inflammatory and oxidative stress inhibitor miRNAs will allow for the possible use of these miRNAs mimics to prevent or reduce inflammation and oxidative stress. Since prolonged inflammation will eventually lead to fibrosis and renal damage, early intervention is necessary to prevent more severe complications.

### LncRNAs in Oxidative Stress and Inflammation {#s4_2_2}

A few lncRNAs also regulate renal inflammation and oxidative stress, though limited evidence is available. LncRNA GM4419 is a regulator for NF-κB signaling by directly interacts with the p50 protein, and thus, an increase of its expression promotes the inflammatory responses in renal mesangial cells upon stimulation of high glucose ([@B154]). Inhibition of this lncRNA significantly led to the reduction of inflammation and fibrosis ([@B154]). Another reported pro-inflammatory lncRNA is the Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) that was increased in DN mice and interacted with serum amyloid A3 (*Saa3*), subsequently promotes the production of inflammatory factors (Il6 and Tnfa) in those DN mice ([@B108]). Similarly, the upregulation of lncRNA GM6135 expression in DN mice also promoted inflammation by increasing the expression of *TLR4*, which is a component of TLR‐mediated signaling that is responsible for the secretion of pro-inflammatory cytokines ([@B63]).

In contrast, Myocardial infarction-associated transcript (MIAT) lncRNA is a protective lncRNA for the renal oxidative stress, by increasing the *Nrf2* expression, a regulator of the antioxidant genes in DN mice ([@B164]). In an animal model of DN, MIAT expression negatively correlated with serum creatinine level ([@B164]), indicating that higher lncRNA MIAT expression is important for a healthy kidney. In contrast, another study showed that silencing the MIAT expression prevented myofibroblast formation in kidney fibrosis ([@B14]), thus implying that MIAT is a pro-fibrotic lncRNA in tubulointerstitial fibrosis. Interestingly, in this same study ([@B14]), it was the lncRNA RIAN that exhibited the anti-fibrotic role in tubulointerstitial fibrosis. Different roles of MIAT in mediating kidney injury or fibrosis can partially be explained *via* its interaction with miRNA targets in different pathways and mechanisms. For example, MIAT increased aortic vascular smooth muscle cell survival by inhibiting the expression of miR-145 ([@B22]), whereas MIAT promoted cardiac fibrosis *via* suppressing the miR-24 expression, a regulator of cardiac fibrosis genes ([@B37]). Therefore, it is important to unravel these molecular interactions to understand the exact mechanisms of DN progression.

### LncRNA-MiRNA Interactions in Oxidative Stress and Inflammation {#s4_2_3}

Several lncRNAs can regulate oxidative stress and inflammation in DN. Anti-oxidative stress lncRNA, LINC01619 expression was downregulated in DN patients' renal tissues, and since LINC01619 acts a sponge to miR-27a, and this reduction of LINC01619 expression causing miR-27a-mediated inhibition of *FOXO1* expression, thus consequently leads to the ER stress and podocyte cells injury in DN ([@B9]). Intriguingly, miR-27a also negatively regulates *NRF2* and *PPARG* expressions, which are the anti-inflammatory factors ([@B55]; [@B119]; [@B166]). Thus, restoration of LINC01619 expression can prevent oxidative stress, inflammation, and podocyte cell injury in DN. Unlike LINC01619, the pro-inflammatory lncRNA, MALAT-1 was increased in DN rats and was shown to inhibit miR-23c expression by competitive binding, and thus increasing the expression of miR-23c targets, the pro-inflammatory proteins (ELAVL1, NLRP3, CASP1, and IL1B) in human kidney proximal tubular epithelial cells ([@B83]). Another miRNA target of MALAT-1 is miR-449, in which the suppression of miR-449 action led to an increase of the *PAI1* expression ([@B40]). This suppression of miR-449 expression correlated with the reduced GFR readings and increased uric acid and triglycerides in the blood of DN patients ([@B40]). Similar to MALAT-1, pro-inflammatory lncRNA, GM6135 increases the expression of *Tlr4*, by competitive binding to miR-203-3p, thus further activates the secretion of pro-inflammatory cytokines in DN mice ([@B63]). Interestingly, miR-874 also negatively regulates the *Tlr4* gene expression ([@B152]). Thus further works are needed to determine whether lncRNA GM6135 could interact with miR-874 and elevates *TLR4* expression. Nevertheless, inhibition of these pro-inflammatory lncRNAs may alleviate the inflammatory response in renal cells *via* the up-regulation of their target miRNAs.

Autophagy and Apoptosis {#s4_3}
-----------------------

### MicroRNAs in Autophagy and Apoptosis {#s4_3_1}

Prolonged oxidative stress and inflammation can induce autophagy, apoptosis, and fibrosis in the kidney. In a study of human renal proximal tubular cells treated with high glucose concentration, overexpression of miR-155-5p led to the suppression of Sirtuin-1 (*SIRT1*) expression, which is a well-known anti-apoptotic, anti-fibrotic and anti-inflammatory factor, and together with reduction of the two autophagy genes, *LC3-II* and *ATG5* ([@B139]). Consistent with this, in microalbuminuria patients, urinary exosome expression of miR-130a and miR-145 were higher, whereas miR-155 and miR-424 expression were reduced ([@B10]). Another pro-fibrotic miRNA is the miR-133b, and its low expression in DN patients was in response to *TGFB1* induction ([@B37]). This increased miR-133b expression inhibits E-cadherin (*CDH1*) and *SIRT1* expression, as shown in DN mice ([@B124]). Inhibition of miR-133b and miR-199b expression attenuated TGFB1 action, *via* the upregulation of *SIRT1* expression ([@B124]). Similar to *SIRT1*, Sirtuin-7 (*SIRT7*) expression is also important to prevent podocyte cells apoptosis, and low *SIRT7* expression in hyperglycemic podocyte cells and DN mice, was due to being negatively regulated by miR-20b ([@B134]) Besides that, the miR-30 family members are also anti-fibrotic miRNAs, in which their expressions are reduced in DN patients ([@B37]). Their common target, a connective tissue growth factor (*CTGF*), is a potent regulator for fibrosis, and its expression was higher in DN ([@B144]). Another regulator of *CTFG* is miR-26a, and its expression was low in DN patients and animal models ([@B72]).

In terms of apoptosis and cell death, miR-503 expression was higher in DN mice, and it negatively inhibits the expression of E2F transcription factor 3 (*E2f3*), and E2f3 is the transcription factor that is involved in the regulation of cell apoptosis, differentiation, and development ([@B156]). Reduction of the *E2f3* expression leads to podocyte cells apoptosis and injury, induced by high glucose ([@B156]). Importantly, in the mice model of DN treated with Losartan (a drug for kidney disease treatment), the prevention of DN progression in those mice was evident with the inhibition of miR-503 action ([@B167]), therefore confirming the role of miR-503 in contributing to podocyte cell death. Similarly, miR-181b is also the pro-apoptotic miRNA, and its expression was high in DN patients ([@B168]). Increased miR-181b expression caused a reduction of *TIMP3* expression, and inhibition of miR-181b caused up-regulation of *TIMP3* expression together with increased mesangial cell viability ([@B168]). Other pro-apoptotic miRNAs are the miR-770-5p that negatively regulates TP53-regulated inhibitor of apoptosis-1 (*Triap1*) expression in mice podocytes ([@B162]); miR-320 that negatively regulates the transcription factor, *Mafb* in DN mice ([@B53]); miR-182-5p that negatively regulates *FOXO1*, actin scaffolding protein (*CD2AP*), and the regulator of cell death, *BCL2* expressions in both human and animal models of DN ([@B121]; [@B106]; [@B101]); miR-134-5p that negatively regulates *Bcl2* expression in DN mice ([@B110]); and all of these miRNAs were upregulated in DN and thus contributing to podocyte cell death. In contrast to that, miR-29a is anti-apoptotic miRNA in which its expression was low in DN mice that negatively regulates cannabinoid type-1 receptor (*Cnr1*) expression ([@B86]; [@B127]), and overexpression of miR-29a in animal model of DN prevented the secretion of pro-inflammatory and pro-fibrogenic factors, consequently attenuated renal hypertrophy ([@B127]). These findings provide the basis of using miRNAs as a therapeutic strategy to prevent or reduce the progression of DN. However, it is important to note that many of these miRNAs also regulate different targets at the same time ([@B118]), thus may unnecessarily causing dysregulation in a completely different pathway. Therefore, recent studies have embarked to characterize and develop these miRNA-based therapies for DN.

### LncRNAs in Autophagy and Apoptosis {#s4_3_2}

In terms of renal autophagy and apoptosis, lncRNA GM5524 expression was increased in DN mice and regulated these processes, upon stimulation with high glucose ([@B41]). GM5524 inhibits anti-apoptotic *BCL2* expression and activates the LC3/ATG signaling pathway to promote autophagy ([@B41]). LncRNA GAS5 is also a pro-apoptotic lncRNA, in which GAS5 promoted the human renal tubular epithelial cells apoptosis under high glucose environment ([@B92]) In contrast to that, lncRNA GM15645 expression was low in DN mice and podocyte cells upon stimulation of high glucose, and this lncRNA acts opposite to lncRNA GM5524 in the regulation of podocyte cells apoptosis and autophagy ([@B41]). Similar to the anti-apoptotic effects of GM15645, lncRNA Taurine upregulated-1 (TUG-1), was downregulated in the DN and hyperglycemic condition, with evidence of renal damage and loss of podocyte cells in DN patients and animal model ([@B78]; [@B117]). Loss of TUG-1 expression reduces peroxisome proliferator-activated receptor gamma coactivator 1-alpha (*Ppargc1a*) expression, as TUG-1 binds to the promoter region of the *Ppargc1a* gene to increase its expression ([@B90]). Consequently, loss of TUG-1 expression increases the tumor necrosis factor receptor-associated factor 5 (*Traf5*) expression and stimulates the podocyte cell death ([@B78]). Restoration of TUG-1 expression inhibits Traf5 protein production, not its mRNAs expression, and ameliorates podocyte cell survival ([@B78]). Another anti-apoptotic lncRNA is lncRNA NR_033515, in which its circulating expression was higher in DN patients, and this NR_033515 lncRNA can inhibit apoptosis by increasing the expression of proliferation genes (*PCNA* and *CCND1*) and fibrotic genes (*P38, ASK1, FN, and α-SMA*) ([@B44]). Recently, Cancer susceptibility candidate 2 (CASC2) lncRNA has diagnostic potential for renal failure, as its reduced expression correlated with most significant renal damage in DN patients ([@B135]). CASC2 prevents podocyte cell apoptosis through the inhibition of JNK signaling ([@B149]). Although these findings of lncRNAs' role in DN progression is still lacking, there are potential biomarkers and therapeutic targets from these lncRNAs, particularly the anti-inflammatory lncRNA, MIAT, and anti-apoptotic lncRNA, TUG-1.

### LncRNAs-miRNAs Interactions in Autophagy and Apoptosis {#s4_3_3}

In terms of renal autophagy and apoptosis, lncRNA NR_033515 expression was higher in DN patients, and it inhibits miR-743b-5p action, and consequently increases the proliferation genes (*PCNA* and *CCND1*), and fibrogenesis genes (*P38, ASK1, FN, and α-SMA*) ([@B44]). Similarly, LncRNA 1700020I14Rik inhibits the miR-34a-5p expression and increases the Sirt1/Hif-1α signaling pathway, thus promotes the cell proliferation and fibrotic gene expressions (*Tgfb1*, *Fn*, and *Col4a1*) in DN mice ([@B84]). The pro-apoptotic role of lncRNA GAS5 was due by its competitive binding towards miR-27a ([@B92]). In hyperglycemic condition, GAS5 inhibits the regulatory action of miR-27a towards the BCL2 Interacting Protein 3 (*BNIP3*), thus causing an upregulation of *BNIP3* expression and renal tubular epithelial cell apoptosis ([@B92]). Another lncRNA is the lncRNA XIST, in which its expression was high in patients with primary membranous nephropathy, and this high expression of lncRNA XIST was due to Ang II treatment that promotes podocyte apoptosis ([@B65]). In this study, higher expression of lncRNA XIST inhibited the miR-217 action from suppressing the *TLR4* expression; thus, leads to TRL4 activation of inflammatory and apoptosis effects ([@B65]). Interestingly, lncRNA XIST expression can be detected in the urine samples ([@B58]) thus suggesting the potential of this lncRNA as a biomarker for DN. From this evidence of lncRNA-miRNA interactions, there are two types of lncRNA regulations involved. One is that lncRNAs host the miRNAs and positively regulates these miRNAs. The second action is that lncRNAs act as a sponge to inhibit the miRNAs suppression of their target genes. Therefore, by identifying these interactions in the molecular regulation of DN progression, some of these lncRNAs can be used as potential biomarkers and therapeutic targets.

### CircRNAs-lncRNAs-miRNAs Interactions in DN {#s4_3_4}

Limited evidence is available to elucidate the interaction of circular RNA in DN progression. Only one study in DN mice showed that circRNA_15698 expression was higher in the DN mice, and knockdown expression of circRNA_15698 in mesangial cells led to reduced expression fibrotic genes (*Col1a1*, *Col4a1,* and *Fn*) ([@B57]). In this study ([@B57]), circRNA_15698 acts as a sponge to miR-185, which in returns upregulates *TGFB1* expression and promotes the ECM protein production. Therefore, inhibition of circRNA_15698 expression can prevent *Tgfb1*-mediated ECM accumulation and fibrosis in DN. Despite that there is limited information available for circRNAs in DN, the current findings imply that these circRNAs may be involved in DN progression, and the most exciting part is how their roles as miRNA sponge may interact with known lncRNA-miRNA interaction discussed above.

LncRNA-miRNA-Based Treatment for DN {#s4_4}
-----------------------------------

MiRNAs can control the expression of genes involved in disease: thus, many miRNA-based therapies potentially can be as the alternative treatment options. In order for the miRNA-based treatment to work, the application of chemically engineered oligonucleotides to mimic (miRNA mimics) or silence the microRNAs (antagomiRs) were developed ([@B115]). One example of such techniques is the locked nucleic acid (LNA) molecular inhibitor to suppress a particular miRNA expression or action ([@B115]). Interestingly, LNA-miR-192 (to reduce miR-192 expression), showed some potential as a treatment for DN, as it reduces the downstream miRNAs expression following the TGFB response, and the expression of critical genes in fibrosis progression in mice model ([@B109]). In agreement with most of the current treatments are available for DN patients, the application of the miRNA-based treatment in DN is mainly focused on to prevent renal fibrosis. Subcutaneous injection of antagomiR-miR-21 prevented renal fibrosis in chronic kidney disease mice by preventing both glomerular and tubular cell damage ([@B47]). Another study focused on miR-29 family, in which the restoration of miR-29b expression in DN mice resulted in TGF-β/Smad3 pathway suppression, reduced collagen matrix accumulation and inflammation ([@B19]), thus implying that miRNA-based treatment could potentially be an alternative option for DN.

Although miRNA-based treatment is positively encouraging, the problem lies within the delivery method to exert this miRNA-based treatment. Most miRNAs are known to regulate many other target genes at the same time ([@B20]; [@B80]); thus, this treatment option may affect other un-related pathways, if they are delivered as a whole-body effect or *in vivo*. Therefore, current research in miRNA-based therapies is shifted to focus on the delivery efficacy and safety, either by using a vector (virus particles or lipid particles) to target a specific route and localization to ensure a local tissue or region effect ([@B77]; [@B118]). Moreover, consideration of the therapeutic agent's size is also needed to make sure that it is small enough to cross the endothelium to the organ or site of interest and not will be filtered out by the kidney ([@B115]). However, for treating DN, this filtration problem could be an advantage to the miRNA-based treatment, as the tubular epithelial cells tend to reabsorb the molecules from the ultra-filtrate, thus reducing the loss ([@B115]). Therefore, there is some promise that miRNA-based treatments can be used for DN patients, though more future works are needed to validate these, especially in human clinical trials.

Several miRNA-based treatment or drugs have advanced to human clinical trials, though none was for treating DN. One such example is Miravirsen, which is a miR-122 inhibitor (LNA-antisense oligonucleotide) that already entered phase II clinical trials to treat HCV infection in patients ([@B60]). Subcutaneous Miravirsen injections resulted in dose-dependent reductions in HCV RNA levels without evidence of viral resistance ([@B60]). Similarly, RG-101, which is another miR-122 inhibitor for HCV-infected patients, has already completed a phase I trial ([@B129]). Many other miRNA-based treatments are currently in the development pipeline to initiate clinical trials for different human diseases; therefore, the option to use miRNA-based treatment for DN is a new research interest.

Another possible treatment is using the lncRNAs for DN. Targeting the lncRNA expression is favorable when compared to miRNAs, due to its functional role in transcriptional regulation, tissue-specific expression, cell- and disease-specific dysregulation. Because of the lncRNAs are predominantly in the nucleus, modified antisense oligonucleotides (ASOs) are used to target or silence the lncRNA in the nucleus by initiating the RNase H--dependent degradation ([@B76]). Such examples are the 2′-OMe RNA and LNA modifications at both the 5′ and the 3′ end ([@B76]). Though, the challenge is to make sure that the ASO binding is as intended to the lncRNA specific site, as the tertiary and secondary structures of lncRNAs can block such binding ([@B2]). Hence, to ensure the binding happens, the only solution is to provide or design more modified ASOs to target a single lncRNA, but the cost of each will be expensive. Moreover, the real challenge is the application of using this lncRNA-based treatment *in vivo*, and similar to miRNA-based treatments, the problems lie within their efficient delivery and efficacy. Another problem lies in the heterogeneous nature and un-conserved intron sequence of lncRNAs ([@B45]). Therefore, for some lncRNAs, a specific sequence of inhibitor needs to be designed specifically for each of them, mainly if the lncRNAs are from the animal models. Hence, further works need to be done to determine the possibility of using these miRNAs/lncRNAs-based treatments in DN progression as a future treatment option.

Conclusion {#s5}
==========

Many ncRNAs (miRNAs, lncRNAs, and circRNAs) are actively discovered to be involved in DN progression due to their regulations of the critical genes in these processes. Since most of these ncRNAs are stable in the biological fluids and can be identified easily without the surgical approach, they provide a strong basis as the potential biomarkers or therapeutic targets. Some of these ncRNAs are very specific towards their targets and localization. Although the exact molecular mechanism of DN progression is still unknown, several processes and pathways are known. Among these processes, ncRNAs involve in renal fibrosis and hypertrophy, ECM protein accumulation, cell autophagy, and apoptosis. Thus, concurrent with ncRNAs characterization, some research has proceeded to synthesize and producing ncRNAs-based treatments, with a few of these ncRNAs are already in the clinical trial phase. Therefore, these ncRNAs-based treatments will be an option for the treatment of DN in the future.
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